巨额套现仍缺钱？老百姓控股股东再质押

Core Viewpoint - The announcement reveals that the controlling shareholder, Lao Bai Xi Medicine Group, has pledged 14 million shares of Lao Bai Xi Pharmacy, which raises concerns about the company's financial stability and stock performance [1] Share Pledge Situation - The total number of shares pledged by the controlling shareholder amounts to 114 million, representing 63.25% of their holdings and 15.04% of the company's total share capital [1][2] - The pledge is intended to meet the operational needs of the medicine group, which claims to have the ability to repay the funds, with repayment sources including dividends from the listed company and self-raised funds [2][3] Future Pledge and Reduction Plans - In the next six months, 12.35 million shares are set to mature, accounting for 6.84% of the controlling shareholder's holdings and 1.63% of the company's total shares, with a corresponding financing amount of 100 million [3] - The medicine group plans to reduce its holdings by 18.11 million shares between June 20 and July 30, 2025, at a price range of 17.60 to 21.55 yuan per share, totaling approximately 341 million [4] Financial Performance - Recent financial results show that the company experienced a revenue decline of 0.36% year-on-year in 2024, with a net profit drop of 44.13% [5] - For the first three quarters of 2025, both revenue and net profit continued to decline, with decreases of 1% and 16.11%, respectively [5] - The company's stock price has fallen over 70% from its peak of 53.14 yuan per share in 2020, closing at 15.26 yuan per share with a total market capitalization of 11.58 billion [5]